Form 4: Align Technology Director Equity Vesting and Grant

Director Kevin T. Conroy acquired 1,745 shares of Align Technology common stock via RSU vesting and received a new grant of 1,836 RSUs.

Summary

• Director Kevin T. Conroy exercised and settled 1,745 restricted stock units (RSUs) on May 20, 2026.
• Following the settlement, the director's total direct beneficial ownership of common stock increased to 3,553 shares.
• The director was granted a new award of 1,836 RSUs on May 20, 2026, which are scheduled to vest on May 20, 2027, or the date of the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director equity compensation.

Positives

• The transaction reflects standard equity compensation alignment between the director and the company's long-term performance.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The new RSU grant is expected to vest on May 20, 2027, or the date of the next annual meeting, subject to continued service.

Industry Context

StockSavvy.ai notes that this filing represents routine equity compensation activity for a board member, which is standard practice for publicly traded medical device companies to ensure director alignment with shareholder interests.

Comparison to Industry Standards

• The equity compensation structure is consistent with standard corporate governance practices for S&P 500 companies.
• The use of RSUs as a primary vehicle for director compensation is common among peers in the healthcare technology sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 1,836 RSUs on May 20, 2027.

Key Dates

Keywords

Align Technology, ALGN, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units